0001127602-24-015998.txt : 20240520
0001127602-24-015998.hdr.sgml : 20240520
20240520165433
ACCESSION NUMBER: 0001127602-24-015998
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240516
FILED AS OF DATE: 20240520
DATE AS OF CHANGE: 20240520
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: DEKKERS MARIJN E
CENTRAL INDEX KEY: 0001216068
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40097
FILM NUMBER: 24965394
MAIL ADDRESS:
STREET 1: GENERAL ELECTRIC COMPANY
STREET 2: 41 FARNSWORTH STREET
CITY: BOSTON
STATE: MA
ZIP: 02210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Ginkgo Bioworks Holdings, Inc.
CENTRAL INDEX KEY: 0001830214
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 872652913
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 27 DRYDOCK AVENUE
STREET 2: 8TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: (877) 442-5362
MAIL ADDRESS:
STREET 1: 27 DRYDOCK AVENUE
STREET 2: 8TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: Soaring Eagle Acquisition Corp.
DATE OF NAME CHANGE: 20210210
FORMER COMPANY:
FORMER CONFORMED NAME: Spinning Eagle Acquisition Corp.
DATE OF NAME CHANGE: 20201027
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2024-05-16
0001830214
Ginkgo Bioworks Holdings, Inc.
DNA
0001216068
DEKKERS MARIJN E
C/O GINKGO BIOWORKS HOLDINGS, INC.
27 DRYDOCK AVENUE
BOSTON
MA
02210
1
0
Class A Common Stock
2024-05-16
4
S
0
265000
.8303
D
5515364
I
By Novalis LifeSciences Investments I, L.P.
Class A Common Stock
281217
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.8233 to $0.8387, inclusive. The Reporting Person undertakes to provide to the Issuer, any security
holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Includes 464,481 earn-out shares that will vest in substantially equal installments if the Issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $15.00, $17.50 and $20.00.
The reporting person is the manager of the general partner of Novalis LifeSciences Investments I, L.P. ("Novalis LifeSciences"), and as such, has sole voting and dispositive power over the shares held by Novalis LifeSciences and, as a result, may be deemed to share beneficial ownership of the shares held by Novalis LifeSciences.
Includes 281,217 earn-out shares that will vest in substantially equal installments if the Issuer's Class A Common Stock achieves a price per share for any period of 20 trading days out of 30 consecutive trading days prior to September 16, 2026 that equals or exceeds the following thresholds: $15.00, $17.50 and $20.00.
/s/ Karen Tepichin, Attorney-in-Fact
2024-05-20